The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion by Tsung, Allan et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 201, No. 7, April 4, 2005 1135–1143 www.jem.org/cgi/doi/10.1084/jem.20042614
 
ARTICLE
 
1135
 
The nuclear factor HMGB1 mediates hepatic 
injury after murine liver ischemia-reperfusion
 
Allan Tsung,
 
1
 
 Rohit Sahai,
 
1
 
 Hiroyuki Tanaka,
 
1
 
 Atsunori Nakao,
 
1
 
 
Mitchell P. Fink,
 
1,2
 
 Michael T. Lotze,
 
1
 
 Huan Yang,
 
3
 
 Jianhua Li,
 
3
 
 
 
Kevin J. Tracey,
 
3
 
 David A. Geller,
 
1
 
 and Timothy R. Billiar
 
1
 
1
 
Department of Surgery and 
 
2
 
Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA 15213
 
3
 
Laboratory of Biomedical Science, North Shore University Hospital, New York University School of Medicine, Manhasset, NY 11030
 
High-mobility group box 1 (HMGB1) is a nuclear factor that is released extracellularly as a 
late mediator of lethality in sepsis as well as after necrotic, but not apoptotic, death. Here 
we demonstrate that in contrast to the delayed role of HMGB1 in the systemic inflammation 
of sepsis, HMGB1 acts as an early mediator of inflammation and organ damage in hepatic 
ischemia reperfusion (I/R) injury. HMGB1 levels were increased during liver I/R as early as 
1 h after reperfusion and then increased in a time-dependent manner up to 24 h. Inhibition 
of HMGB1 activity with neutralizing antibody significantly decreased liver damage after I/R, 
whereas administration of recombinant HMGB1 worsened I/R injury. Treatment with 
neutralizing antibody was associated with less phosphorylation of c-Jun NH
 
2
 
-terminal 
kinase and higher nuclear factor–
 
 
 
B DNA binding in the liver after I/R. Toll-like receptor 4 
(TLR4)-defective (C3H/Hej) mice exhibited less damage in the hepatic I/R model than did 
wild-type (C3H/HeOuj) mice. Anti-HMGB1 antibody failed to provide protection in C3H/Hej 
mice, but successfully reduced damage in C3H/Ouj mice. Together, these results demonstrate 
that HMGB1 is an early mediator of injury and inflammation in liver I/R and implicates TLR4 
as one of the receptors that is involved in the process.
 
Ischemia reperfusion (I/R) injury is a patho-
physiologic process whereby hypoxic organ
damage is accentuated following return of blood
flow and oxygen delivery. Transient episodes of
ischemia are encountered during solid organ
transplantation, trauma, hypovolemic shock, and
elective liver resection, when inflow occlusion or
total vascular exclusion is used to minimize
blood loss. The pathophysiology of liver I/R
injury includes direct cellular damage as the re-
sult of the ischemic insult as well as delayed
dysfunction and damage that results from activa-
tion of inflammatory pathways. Histopathologic
changes include cellular swelling, vacuolization,
endothelial cell disruption, neutrophil infiltra-
tion, and hepatocellular necrosis (1, 2).
The distal cascade of inflammatory re-
sponses that result in organ damage after I/R
injury has been studied extensively (3–8). Activa-
tion of Kupffer cells with production of reactive
oxygen species, up-regulation of the inducible
nitric oxide synthase, up-regulation of proin-
flammatory cytokines, and neutrophil accu-
mulation have been identified as contributing
events to the inflammation-associated damage.
The extent to which the initial cellular injury
contributes to propagation of the inflammatory
response and further tissue damage is poorly
understood.
We propose that a key link between the
initial damage to cells and the activation of
inflammatory signaling involves endogenous
danger signals from ischemic cells. High-mobility
group box 1 (HMGB1) recently was identified
as an inflammatory cytokine that is involved as
a late mediator of lethality in sepsis (9, 10).
The observation that HMGB1 that is released
from necrotic cells can serve as a mediator of
inflammation in in vitro systems (11) points to
this protein as a regulator for the inflammation
that is seen following acute tissue damage. Re-
cent in vitro studies suggests that some of the
effects of HMGB1 result from its interaction
with the individual members of the Toll-like
receptor (TLR) family, TLR2 and TLR4 (12).
Interaction of HMGB1 with TLR4, as we
demonstrate here, could provide a critical link
between tissue damage and activation of the
innate immune response.
The aim of this study was to test the hy-
pothesis that HMGB1 is an early mediator of
inflammation and cell injury after hepatic I/R
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and that the actions of HMGB1 require TLR4. We show
that HMGB1 is up-regulated in cultured hepatocytes by hy-
poxia and warm hepatic I/R in vivo. Neutralizing antibody
to HMGB1 prevents hepatocellular damage and suppresses
the activation of inflammatory cascades. In addition, we
show that the TLR4 system plays a key role in the mecha-
nism of hepatic I/R injury and implicate a HMGB1-TLR4
interaction in hepatic I/R.
 
RESULTS
Pretreatment with neutralizing antibody to HMGB1 protects 
against liver I/R injury
 
To determine if endogenous HMGB1 contributed to organ
damage after liver I/R, neutralizing antibody to HMGB1
was administered to mice that were subjected to warm I/R.
Animals were given anti-HMGB1 antibody (600 
 
 
 
g or 60
 
 
 
g per mouse) or irrelevant IgG antibody 1 h before is-
chemia. Sixty minutes of warm hepatic ischemia followed by
6 h of reperfusion significantly increased serum alanine ami-
notransferase (sALT) levels in the IgG antibody control mice
that were subjected to I/R. Treatment with 60 
 
 
 
g of anti-
HMGB1 antibody did not confer any protection, whereas
treatment with 600 
 
 
 
g of anti-HMGB1 antibody resulted in
significant protection from hepatic injury (Fig. 1 a). This
protection also was evident at 24 h after reperfusion in anti-
HMGB1 antibody–treated mice (Fig.
 
 
 
1 b). Liver histology
confirmed the sALT estimation of liver damage. Severe si-
nusoidal congestion and hepatocellular necrosis was present
in liver tissue from mice that were treated with control IgG,
whereas minimal damage was noted in samples from anti-
HMGB1–treated mice (Fig. 1 c). Liver samples from control
animals exhibited 
 
 
 
26.9 
 
 
 
 6.2% necrotic hepatocytes com-
pared with 5.3 
 
 
 
 1.1% necrotic cells in the anti-HMGB1–
treated group (
 
n
 
 
 
 
 
 6 per group; P 
 
 
 
 0.05).
 
HMGB1 expression is up-regulated in hepatocytes after 
hypoxia in vitro and in the liver in vivo after I/R
 
To determine if the HMGB1-dependent injury was associ-
ated with changes in protein levels, Western blot analysis
was performed on liver lysates from animals that were sub-
jected to liver I/R (Fig. 2 a). Following 60 min of warm
ischemia, HMGB1 protein expression was up-regulated as
early as 1 h after reperfusion and then increased in a time-
dependent manner up to 24 h. Previous studies have shown
that HMGB1 localizes predominantly in the nucleus of mac-
rophages (11). To determine the cellular localization of
HMGB1 in the liver, immunofluorescence staining was per-
formed in normal livers and livers that underwent I/R. Ex-
pression of HMGB1 was noted predominantly in the nu-
cleus of hepatocytes in normal livers (Fig. 2 b). After
ischemia and 6 h of reperfusion, HMGB1 expression was
enhanced in the nucleus and cytoplasm of hepatocytes (Fig.
2 c). Although HMGB1 expression was increased in the
liver, we were unable to detect increased HMGB1 levels in
the serum of mice that underwent hepatic I/R injury (data
not shown).
Hypoxia is believed to be the initiating event in the I/R
insult; therefore, we assessed the expression of HMGB1 in
hepatocytes that were exposed to hypoxia in vitro. Primary
rat hepatocytes that were exposed to normoxia (21% oxy-
gen) had a basal level of HMGB1 expression which did not
change significantly up to 24 h of incubation (data not
shown). However, exposure of the hepatocytes to hypoxia
(1% oxygen) resulted in a time-dependent increase in cellu-
lar HMGB1 expression (Fig. 2 d). HMGB1 also increased in
the media of hepatocytes that were exposed to hypoxia. Cell
viability was not different between hepatocytes that were ex-
posed to hypoxia and normoxia at 24 h (data not shown).
 
Delayed administration of neutralizing antibody to HMGB1 
protects against liver I/R injury
 
Although administration of neutralizing antibody to HMGB1
that was given as a pretreatment was protective in our model
of liver I/R injury, strategies that use this antibody after the
onset of injury would be clinically relevant. We next sought
to determine the efficacy of the antibody given after the
ischemic event. In I/R injury, the cascade of events that re-
Figure 1. Pretreatment with neutralizing antibody to HMGB1 pro-
tects against liver I/R injury. (a) Sham mice and mice that underwent 
ischemia and 6 h of reperfusion were treated with anti-HMGB1 antibody 
(60  g or 600  g) or control antibody i.p. 1 h before ischemia. Serum ALT 
levels were analyzed as a measure of hepatocellular injury. Data represent 
means   SE, n   six mice per group. *P   0.05 versus mice subjected to 
I/R given control antibody. (b) Sham mice and mice that underwent ischemia 
and 24 h of reperfusion were treated with anti-HMGB1 antibody (600  g) 
or control antibody i.p. 1 h before ischemia. Data represent means   SE, 
n   six mice per group. *P   0.05 versus mice that were subjected to I/R 
and given control antibody. (c) Hematoxylin-eosin–stained liver sections 
from control antibody and anti-HMGB1 antibody–treated animals 24 h 
after reperfusion (original magnification  200). Images are representative 
liver sections from six mice per group. 
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sult in organ damage is initiated at the onset of ischemia;
ischemia alone was shown to result in the activation of early
signaling pathways in the liver (13). To determine whether
antibody treatment could be delayed until after ischemia,
anti-HMGB1 antibody (600 
 
 
 
g) was given to the animals
immediately after reperfusion. As with pretreatment, the de-
layed treatment of neutralizing antibodies to HMGB1 also
conferred significant protection against hepatic injury 6 h af-
ter reperfusion (Fig. 3).
 
Neutralizing antibody to HMGB1 decreases production of 
inflammatory mediators
 
Inflammatory cytokines, such as TNF and IL-6, were shown
to play key roles in the pathophysiology of hepatic I/R in-
jury (14, 15). Using real-time RT-PCR, we measured
steady-state mRNA levels for these cytokines in the liver af-
ter I/R. Compared with sham-treated animals, liver I/R in
IgG-treated animals resulted in increased expression of TNF
and IL-6 mRNA 1 h after reperfusion (Fig. 4, a and b).
However, animals that were treated with anti-HMGB1 anti-
body exhibited minimal increases in hepatic TNF and IL-6
mRNA levels compared with control animals that were sub-
jected to I/R. We showed previously that inducible NO
synthase (iNOS) contributes to liver injury that is due to I/R
(16, 17). Hepatic iNOS mRNA levels were increased 1 h af-
ter reperfusion in antibody control–treated mice compared
with sham animals (Fig. 4 c). As with TNF and IL-6 expres-
sion, treatment with anti-HMGB1 prevented hepatic iNOS
expression after I/R.
 
Neutralizing antibody to HMGB1 modulates inflammatory 
signaling pathways
 
Among the most proximal events in I/R is the activation of
mitogen-activated protein (MAP) kinases. A role for c-Jun
NH
 
2
 
-terminal kinase (JNK) activation in liver I/R injury has
been demonstrated (18, 19). To determine if HMGB1 influ-
enced MAP kinase activation, we assessed phosphorylation
of JNK, p38, and extracellular signal-regulated kinase
(ERK). After I/R, phosphorylation of JNK, p38, and ERK
was increased in liver tissue from animals that were treated
with the control IgG (Fig. 5 a). In contrast, when mice were
treated with anti-HMGB1 antibody, phosphorylation of
these MAP kinases was decreased. Treatment with anti-
HMGB1 antibody did not affect total cellular levels of ERK,
p38, or JNK. Thus, these results suggest that HMGB1 acts
upstream of MAP kinase activation. NF-
 
 
 
B activation also
was shown to be increased following hepatic I/R (20).
When activated in hepatocytes, NF-
 
 
 
B prevents cell death
(21). Using electrophorectic mobility shift assays, there was
an increase in NF-
 
 
 
B DNA binding in the ischemic liver 1 h
after reperfusion in control IgG-treated animals compared
with sham-treated animals (Fig. 5 b). Animals that were
treated with neutralizing anti-HMGB1 antibody had an
even greater increase in NF-
 
 
 
B DNA binding. The NF-
 
 
 
B
bands were specific as confirmed by cold competition in the
Figure 2. HMGB1 expression is up-regulated in hepatocytes by hy-
poxia and in the liver after I/R. (a) Mice underwent 60 min of ischemia 
and various lengths of reperfusion. Western blot analysis for cellular 
HMGB1 was performed for hepatic protein lysates of the ischemic lobes at 
the time points shown, with each lane representing a separate animal. 
Blot shown is representative of three experiments with similar results. 
(b) Immunofluorescent stain of HMGB1 from sections of normal liver and 
(c) liver subjected to 60 min of ischemia and 6 h of reperfusion (original 
magnification  400). Images are representative liver sections from six 
mice per group. Red, HMGB1; blue, nuclei; green, F-actin. (d) Cultured rat 
hepatocytes were exposed to hypoxia (1% O2) from 0 to 24 h. Whole cell 
lystate and media were subjected to Western blot analysis of HMGB1. Blot 
shown is representative of three experiments with similar results.
Figure 3. Delayed administration of neutralizing antibody to 
HMGB1 protects against liver I/R injury. Sham mice and mice that 
underwent ischemia and 6 hours of reperfusion were treated with anti-
HMGB1 antibody (600  g) or control antibody immediately after reperfu-
sion. Serum ALT levels were analyzed as a measure of hepatocellular injury. 
Data represent means   SE, n   six mice per group. *P   0.05 versus 
mice that were subjected to I/R and given control antibody. 
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presence of excess unlabeled NF-
 
 
 
B consensus motif. We
previously performed supershift studies to determine that the
NF-
 
 
 
B complex was a heterodimer composed of p65 and
p50 subunits (22).
 
Administration of recombinant HMGB1 worsens liver I/R injury
 
To determine if exogenous HMGB1 would alter hepatic in-
jury in I/R, a nonlethal dose (20 
 
 
 
g) of recombinant
HMGB1 (rHMGB1)was given to mice immediately after
reperfusion. There was no difference in liver injury as as-
sessed by sALT levels between sham animals that were given
either vehicle (PBS) or this low dose of rHMGB1 (Fig. 6). As
expected, I/R increased sALT levels in PBS-treated animals;
however, animals that were given rHMGB1 had a signifi-
cantly greater increase in liver enzyme levels than controls.
 
HMGB1-mediated I/R injury involves TLR4 system
 
Recent in vitro evidence suggest that TLR4 acts as a recep-
tor to HMGB1 (12). To determine if functional TLR4 was
required for I/R-induced injury in the liver, TLR4-defec-
tive (C3H/Hej) mice and wild-type control (C3H/HeOuj)
mice were subjected to liver I/R. TLR4-defective mice
were protected from hepatic I/R injury compared with
TLR4-intact mice (Fig. 7 a). To shed some light on
whether the reduction in hepatic injury was due to LPS-
TLR4 interaction, CD14
 
 
 
/
 
 
 
 mice were also subjected to
warm I/R. No difference in liver injury was seen between
CD14
 
 
 
/
 
 
 
 and CD14
 
 
 
/
 
 
 
 mice (Fig. 7 b). In addition, treat-
ment of anti-HMGB1 antibody to CD14
 
 
 
/
 
 
 
 and CD14
 
 
 
/
 
 
 
mice protected the animals from I/R injury. To deter-
mine if a HMGB1-TLR4 interaction accounted for the
HMGB1-dependent effect in liver injury from I/R, TLR4-
defective and TLR4-intact animals were pretreated with
anti-HMGB1 antibody. Similar to that seen with C57BL/6
mice, blockade of HMGB1 in TLR4 wild-type animals led
to protection from hepatic I/R damage (Fig. 7 a). How-
ever, this protection was not seen in TLR4-defective mice
who underwent hepatic I/R. We also examined the expres-
Figure 4. Neutralizing antibody to HMGB1 decreases production of 
inflammatory mediators. Hepatic TNF-  (a), IL-6 (b), and iNOS (c) mRNA 
expression were measured after ischemia and 1 h of reperfusion in mice 
that were treated with anti-HMGB1 antibody or control antibody. Results 
were obtained using real time RT-PCR and expressed as relative increase 
of mRNA expression compared with sham animals. Data represents
means   SE, n   eight mice per group. *P   0.05 versus mice that were 
subjected to I/R and given control antibody.
Figure 5. Neutralizing antibody to HMGB1 modulates inflammatory 
signaling pathways. (a) Mitogen-activated protein kinase activation was 
determined in sham mice and mice that underwent ischemia and 1 h of 
reperfusion. Animals were treated with anti-HMGB1 antibody or control 
antibody. Western blot analysis for phosphorylated and total ERK, p38, 
and JNK was performed. Hepatic protein lysates from ischemic lobes were 
obtained; each lane represents a separate animal. Blot shown is represen-
tative of three experiments with similar results. (b) NF- B activation during 
hepatic I/R injury was assessed. Mice that underwent ischemia and 1 h of 
reperfusion were treated with anti-HMGB1 antibody or control antibody. 
Nuclear extracts were prepared from the ischemic livers and subjected to 
electrophoretic mobility shift assay. Assay shown is representative of three 
experiments with similar results. 
JEM VOL. 201, April 4, 2005
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sion of TNF and IL-6 mRNA in the liver after I/R for
these animals. Whereas TLR4 wild-type mice that were
treated with anti-HMGB1 antibody exhibited decreased
hepatic TNF and IL-6 mRNA levels compared with con-
trol I/R animals, there was no difference in expression of
these cytokines after I/R in TLR4-defective mice that were
treated with control antibody or neutralizing antibodies to
HMGB1 (Fig. 8 a). To confirm the role of TLR4 in
HMGB1-mediated liver injury, we administered rHMGB1
to TLR4-defective and wild-type animals. There was no
difference in serum ALT levels between sham animals that
were treated with PBS or rHMGB1 (Fig. 8 b). rHMGB1
worsened liver injury after I/R in TLR4 wild-type mice
but had no effect in TLR4-defective mice.
 
DISCUSSION
 
HMGB1 is an ancient protein that predates speciation with
extraordinary conservation among species, and acts as a nu-
clear protein that promotes transcriptional activation and ac-
cess. Prototypic of other damage-associated molecular pat-
tern molecules, it acts late as a downstream mediator of
systemic inflammation in sepsis (9). Macrophages that are
stimulated with endotoxin secrete HMGB1 after a signifi-
cant delay compared with the release of other cytokines,
such as TNF and IL-1, which are much more immediate
(23). Release of HMGB1 also is released readily from ne-
crotic or damaged cells, and serves as a signal for inflamma-
tion (11, 24). Although blockade of HMGB1 in a model of
massive hepatocyte necrosis from acetaminophen in vivo did
not protect against liver damage, inflammation was reduced
as seen by reduced myeloperoxidase activity in total liver ex-
tracts (11). The purpose of this study was to test the notion
that HMGB1 acts as an early mediator of inflammation and
injury in hepatic I/R injury. The major and novel findings
of this investigation are: (a) HMGB1 levels are increased by
hypoxia in cultured hepatocytes and by I/R in the liver in
vivo; (b) blockade of HMGB1 protects against warm hepatic
I/R injury; (c) the protection is associated with a decrease in
MAP kinase activation, augmented NF-
 
 
 
B activation, and a
decrease in local hepatic proinflammatory cytokine expres-
sion; and (d) evidence for HMGB1–TLR4 interaction in the
mechanism of HMGB1-mediated damage in hepatic I/R.
Whereas HMGB1 is a late mediator of systemic inflam-
mation in sepsis, our findings implicate HMGB1 as an early
mediator following acute, local organ injury. This role for
HMGB1 may include a rapid increase in HMGB1 levels in
the liver. We showed that hepatic HMGB1 expression in-
creases as early as 1 h after reperfusion of ischemic liver. That
hypoxia alone is adequate to increase HMGB1 levels is
shown by our studies with cultured hepatocytes. It is un-
known whether the increases in HMGB1 levels are essential
to the proinflammatory effects. Our observation that even
Figure 6. Administration of recombinant HMGB1 worsens liver I/R 
injury. Serum ALT levels were measured in sham mice and mice that un-
derwent ischemia and 6 h of reperfusion. Animals were treated with a 
nonlethal dose of recombinant HMGB1 (20  g) or vehicle PBS immediately 
after reperfusion. Data represent means   SE, n   four mice per group. 
*P   0.05 versus mice that were subjected to I/R and given vehicle PBS.
Figure 7. Hepatic I/R injury involves TLR4 system and is indepen-
dent of LPS-TLR4 interaction. (a) TLR4-defective mice (C3H/Hej) and 
their wild-type (WT) mice counterparts (C3H/HeOuj) were subjected to 
liver ischemia and 6 h of reperfusion. Animals were treated with anti-
HMGB1 antibody or control antibody 1 h before ischemia and sALT levels 
were measured. Data represent means   SE, n   four to six mice per 
group. *P   0.05 versus TLR4 wild-type mice that were subjected to I/R 
and given control antibody. (b) CD14 /  and CD14    mice were subjected 
to liver ischemia and 6 h of reperfusion. Animals were treated with anti-
HMGB1 antibody or control antibody at reperfusion. Data represent 
means   SE, n   5 mice per group. *, P   0.05 versus CD14    mice sub-
jected to I/R given control antibody. **, P   0.05 versus CD14    mice 
subjected to I/R given control antibody. 
HMGB1 IN HEPATIC ISCHEMIA/REPERFUSION INJURY | Tsung et al.
 
1140
 
early, proximal signaling events (i.e., MAP kinase activation)
are partially HMGB1-dependent suggests that increases in
HMGB1 levels are not essential. It is not known from our
studies whether HMGB1 is secreted or passively released
from damaged cells after I/R injury. It could be that severe
ischemic stress leads to a regulated release or surface expres-
sion of HMGB1 as a danger signaling event. As the injury
progresses and cells begin to die, the release may then be
passive; however, this is yet to be proven. It is notable that
circulating levels of HMGB1 did not increase; this is consis-
tent with a local or paracrine-like action for HMGB1 in this
organ-specific acute injury model.
To elucidate the molecular basis of protection in block-
ing HMGB1, we investigated its effect on the MAP ki-
nase and NF-
 
 
 
B signaling pathways. HMGB1 activates one
or more of these signaling pathways in endothelial cells,
smooth muscle cells, enterocytes, and neutrophils (24–27).
The MAP kinase family represents a group of proteins that
is involved in signal transduction of a variety of cellular
stimuli. The JNK subgroup of MAP kinases, also known as
stress-activated protein kinases, is activated in response to
environmental stresses (28). JNK phosphorylation occurs in
cultured rat hepatocytes following hypoxia alone, with fur-
ther increases upon reoxygenation (13, 29). JNK activation
also has been found in the liver after I/R (17–19, 30) and
hemorrhagic shock (13). The reduction in JNK activation,
as well as p38 and ERK, suggests that HMGB1 accounts, in
part, for MAP kinase activation following I/R. Such is not
the case for NF-
 
 
 
B, where neutralization increased NF-
 
 
 
B
DNA binding activity. Thus, the actions of HMGB1 are
selective in liver I/R. It is possible that the enhanced
NF-
 
 
 
B activation contributed to the protection that was
afforded by HMGB1 neutralization. Although NF-
 
 
 
B acti-
vation leads to proinflammatory gene expression in leuko-
cytes and endothelial cells, it is known to protect hepatocytes
from cell death (21). In vivo, inhibition of NF-
 
 B after
partial hepatectomy results in massive hepatocyte apoptosis
associated with impaired liver function and decreased sur-
vival (31). Following I/R that is associated with liver trans-
plantation, two peaks of NF-kB activation were observed,
and blockade of NF-kB activation worsened the liver
injury (22). Further work is required to elucidate the
mechanisms that are involved in the differential effects of
HMGB1 on MAP kinase and NF- B. Enhanced NF- B
activation is seen in mice that are protected from hepatic I/R
following blockade of the receptor for advanced glycation
end product (30).
To study further the mechanism of HMGB1-mediated
injury in hepatic I/R, we explored the TLR4 system as
a possible signal transduction pathway for extracellular
HMGB1. HMGB1, in vitro, interacts with TLR2, TLR4,
and the receptor for advanced glycation end products for
HMGB1-induced activation of inflammatory signaling (12,
32, 33). The TLRs are one of the components by which the
innate immune system senses the invasion of pathogenic mi-
croorganisms by recognizing specific molecular patterns that
are present in microbial products (34). TLR4 plays a critical
role in endotoxin signaling and was shown to participate in
the recognition of several endogenous ligands, such as hyal-
uronic acid, heparin sulfate, fibrinogen, and perhaps, heat
shock proteins (35–38). The release of these ligands stimu-
lates inflammatory activity through TLR4 signaling. Our
data suggest that the TLR4 system also may play a key role
in HMGB1-mediated hepatic I/R injury; TLR4-defective
mice who undergo hepatic I/R are not affected by the ad-
ministration of rHMGB1 or neutralizing antibodies to HMGB1,
compared with TLR4-intact mice. We hypothesize that the
release of HMGB1 from damaged or necrotic cells may pro-
duce an early inflammatory response by activating the TLR4
system. Further, the protection from hepatic I/R in TLR4-
defective mice may be due to their diminished ability to re-
spond to HMGB1.
In summary, this study documents the contribution of
HMGB1 to hepatic I/R injury. In this model of acute local
tissue injury, HMGB1 seems to act as an early mediator of
inflammation. This is in clear contrast to sepsis, in which its
action is delayed. Our results also suggest that the protective
effects of blocking HMGB1 and the detrimental effects of
rHMGB1 in hepatic I/R are dependent on the activation of
TLR4 signaling. Thus, interventions that inhibit HMGB1
activity may be effective in settings of ischemic liver injury
to minimize organ damage and may be useful in other clini-
Figure 8. HMGB1-mediated I/R injury involves TLR4 system. (a) He-
patic TNF-  and IL-6 mRNA expression were obtained in TLR4-defective 
mice and wild-type mice after ischemia and 6 h of reperfusion. Mice were 
treated with anti-HMGB1 antibody or control antibody. Results are expressed 
as relative increase of mRNA expression compared with sham animals. Data 
represent means   SE, n   four to six mice per group. *P   0.05 versus 
TLR4 wild-type mice that were subjected to I/R and given control antibody. 
(b) Serum ALT levels were determined in TLR4-defective mice and wild-type 
mice after ischemia and 6 h of reperfusion. Animals were treated with re-
combinant HMGB1 or vehicle PBS immediately after reperfusion. Data rep-
resent means   SE, n   four to six mice per group. *P   0.05 versus TLR4 
wild-type mice that were subjected to I/R and given vehicle PBS.JEM VOL. 201, April 4, 2005 1141
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cal settings that are associated with inflammation and cellular
necrosis (39–41).
MATERIALS AND METHODS
Materials. Polyclonal antibodies against HMGB1 and recombinant
HMGB1 were prepared as described previously (10). Polyclonal antibodies
against HMGB1 B box were raised in rabbits and titers were determined by
immunoblotting. Anti-HMGB1 B box antibodies were affinity-purified by
using cyanogens bromide-activated Sepharose beads following standard pro-
cedures. Neutralizing activity of anti-HMGB1 was confirmed in HMGB1-
stimulated macrophage cultures by assay of TNF release. In the presence of
anti-HMGB1 antibody, neutralizing antibody was defined as inhibiting
 80% of HMGB1-induced TNF release. Nonimmune rabbit IgG (item
I5006) was purchased from Sigma-Aldrich.
Animals. Male wild-type (C57BL/6; C3H/HeOuj) and TLR4-defective
(C3H/Hej) mice (8–12-wk-old) were purchased from Jackson Immu-
noResearch Laboratories. Male Sprague-Dawley rats, also pathogen-free
and weighing 350–400 g, were obtained from Charles River Laboratories.
CD14 /  mice were provided by Mason Freeman (Harvard University,
Boston, MA). All animals were maintained in a laminar-flow, specific
pathogen-free atmosphere at the University of Pittsburgh. Animal protocols
were approved by the Animal Care and Use Committee of the University
of Pittsburgh and the experiments were performed in adherence to the Na-
tional Institutes of Health Guidelines for the Use of Laboratory Animals.
Liver ischemia. A nonlethal model of segmental (70%) hepatic warm is-
chemia was used. The I/R protocol was initiated with the abdominal wall
being clipped of hair and cleansed with betadine. Under sodium pentobar-
bital (40 mg/kg, i.p.) and methoxyflurane (inhalation) anesthesia, a midline
laparotomy was performed. With the use of an operating microscope, the
liver hilum was dissected free of surrounding tissue. All structures in the por-
tal triad (hepatic artery, portal vein, bile duct) to the left and median liver
lobes were occluded with a microvascular clamp (Fine Science Tools) for 60
min; reperfusion was initiated by removal of the clamp. This method of seg-
mental hepatic ischemia prevents mesenteric venous congestion by permit-
ting portal decompression through the right and caudate lobes. The abdomen
was covered with a sterile plastic wrap to minimize evaporative loss.
Throughout the ischemic interval, evidence of ischemia was confirmed by
visualizing the pale blanching of the ischemic lobes. The clamp was removed
and gross evidence of reperfusion that was based on immediate color change
was assured before closing the abdomen with continuous 4–0 polypropelene
suture. The absence of ischemic color changes or the lack of response to re-
perfusion was a criterion for immediate sacrifice and exclusion from further
analysis. Temperature was monitored by rectal temperature probe and was
maintained at 37 C by means of a warming pad and heat lamp. At the end of
the observation period following reperfusion, the mice were anesthetized
with inhaled methoxyflurane and were killed by exsanguination.
Experimental design. Mice received anti-HMGB1 antibody (600 or 60
 g per mouse) or nonimmune control IgG (Sigma-Aldrich) by i.p. injec-
tion 1 h before ischemia, or recombinant HMGB1 (10  g per mouse) or
vehicle PBS i.p. immediately after reperfusion. Previous studies showed that
anti-HMGB1 antibody at 600  g/mouse protects against sepsis-induced le-
thality (10). The HMGB1 that was used for these studies contained 219 pg/
 g protein of LPS as measured by the chromogenic Limulus amoebocyte ly-
sate assay (Associates of Cape Cod or BioWhittaker). Sham animals under-
went anesthesia, laparotomy, and exposure of the portal triad without he-
patic ischemia. Animals were killed at predetermined time points (1–24 h)
after reperfusion for serum and liver samples.
Hepatocyte isolation. Hepatocytes were isolated from normal rats by an
in situ collagenase (type IV, Sigma-Aldrich) perfusion technique, modified
as described previously (42). Hepatocytes were separated from the non-
parenchymal cells by two cycles of differential centrifugation (50 g for 2
min) and further purified over a 30% Percoll gradient. Hepatocyte purity
exceeded 98% as assessed by light microscopy, and viability typically was
 95% as determined by trypan blue exclusion assay.
Cell culture and treatment. Hepatocytes (3   106) were plated onto
6-cm gelatin-coated plastic tissue culture dishes. The initial culture medium
was Williams medium E containing 10% calf serum, 15 mM Hepes, 2 mM
L-glutamine, and 100 U/ml of penicillin and streptomycin. Hepatocytes
were allowed to attach to plates overnight. The medium was replaced with
hypoxic medium (equilibrated with 1% O2, 5% CO2, and 94% N2), and
placed into a modular incubator chamber (Billups-Rothenburg), which was
flushed with the same hypoxic gas mixture. All cells were washed with ice-
cold PBS and lysed with 1  lysis buffer that contained freshly added 0.5
mM PMSF, and protein was extracted as described below.
Isolation of nuclear and cytoplasmic proteins. Frozen liver tissues
were suspended in a buffer that contained 10 mM Tris, pH 7.5, 1.5 mM
MgCl2, 10 mM KCl, and 0.1% Triton X-100 and lysed by homogeniza-
tion. Nuclei were recovered by microcentrifugation at 7,500 rpm for 5 min.
The supernatant that contained cytoplasmic and membrane protein was col-
lected and stored at  80 C for Western blot analysis. Nuclear proteins were
extracted at 4 C by gently resuspending the nuclei pellet in buffer that con-
tained 20 mM Tris, pH 7.5, 20% glycerol, 1.5 mM MgCl2, 420 mM NaCl,
0.2 mM EDTA, and 0.1% Triton X-100, followed by 1 h incubation at 4 C
with occasional vortexing. After microcentrifugation at 13,000 revolutions/
min for 15 min at 4 C, the supernatant that contained nuclear protein was
collected. Protein concentration was quantitated with bicinchoninic acid
protein assay reagent (Pierce Chemical Co.).
Liver damage assessment. To assess hepatic function and cellular injury
following liver ischemia, sALT levels were measured using the Opera Clin-
ical Chemistry System (Bayer Co.).
Histopathology. Formalin-fixed liver samples were embedded in paraffin
and cut to 6- m-thick sections. Tissues were stained with hematoxylin-
eosin, and slides were assessed for inflammation and tissue damage. The per-
cent necrotic area was estimated by random evaluation of 10 low-power
fields ( 100) of each hematoxylin-eosin–stained section; the observer was
blinded to treatment group.
Immunohistochemical staining. A segment of the left lobe of the liver
was cryoprotected in 2% paraformaldehyde in PBS overnight and then 30%
sucrose in PBS for another 24 h. It was then embedded and frozen in optimal
cutting temperature compound using liquid nitrogen–cooled isopentane.
These samples were stored at  80 C until ready to be cut. To prepare the
slides, the samples were cut into 6-  sections using a cryostat machine and
placed onto slides. They were left to dry at room temperature overnight and
then stored at  20 C. Immunofluorescent staining for HMGB was begun by
first rehydrating the slides with PBS. Then, nonspecific proteins were blocked
using 2% BSA for 45 min followed by rinses with 0.5% BSA. This was fol-
lowed by placing the primary antibody (anti-HMGB1, BD Biosciences, 1:1,000
in 0.5% BSA) for 60 min. The slides were washed with 0.5% BSA and then
the secondary antibody (goat anti–rabbit cy3, Jackson ImmunoResearch Labo-
ratories, 1:1,000 in 0.5% BSA) was applied for another 60 min. The slides were
rinsed again in BSA and stained for F-actin (phalloidin cy5, Jackson Immu-
noResearch Laboratories, 1:250 in PBS) for 30 min. A nuclear stain, hoechst
dye (bisbenzimide, 1 mg/100 ml), was applied for 30 s. The slides were rinsed
with PBS and a coverslip with gelvatol, a water-soluble mounting media (21 g
polyvinylalcohol, 52 ml water, sodium azide, 106 ml 0.2M Tris buffer), was
placed. Slides were visualized using an Olympus BX51 epi-fluorescence mi-
croscope and digitized with an Olympus color videocamera.
Sodium dodecyl sulfate/polyacrylamide gel electrophoresis and
Western blotting. Western blot analysis for HMGB1, phosphorylated
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(43). Primary polyclonal rabbit antibody to HMGB1 (1:5,000; BD Bio-
sciences), primary polyclonal antibody to phosphorylated ERK, p38, and
JNK (1:1,000; Cell Signaling Technology), and primary polyclonal rat anti-
body to total ERK, p38, and JNK (1:1,000; Santa Cruz Biotechnology,
Inc.) were used for Western blot. Membranes were developed with the Su-
per Signal West Pico chemiluminescent kit (Pierce Chemical Co.) and ex-
posed to film.
SYBR green real-time RT-PCR. Total RNA was extracted from the
liver using the TRIzol reagent (Life Technologies) according to the manu-
facturer’s instruction. mRNA for TNF- , IL-6, and iNOS, and GAPDH
was quantified in duplicate by SYBR Green two-step, real-time RT-PCR.
After removal of potentially contaminating DNA with DNase I (Life Tech-
nologies), 1  g of total RNA from each sample was used for RT with an
oligo dT (Life Technologies) and a Superscript II (Life Technologies) to
generate first-strand cDNA. PCR reaction mixture was prepared using
SYBR Green PCR Master Mix (PE Applied Biosystems) using the primers
as described previously (44, 45). Thermal cycling conditions were 10 min at
95 C followed by 40 cycles of 95 C for 15 s and 60 C for 1 min on an ABI
PRISM 7000 Sequence Detection System (PE Applied Biosystems). Each
gene expression was normalized with GAPDH mRNA content.
Electrophoretic mobility shift assays. NF- B DNA binding activity
was measured by electrophoretic mobility shift assays using nuclear extracts
from liver tissues. The NF- B oligonucleotide (Promega) was based on the
NF- B sequence in the immunoglobulin light-chain enhancer. DNA
probes were prepared by end labeling with  -[32P]dATP (Dupont, Merck
Pharmaceuticals) and T4 polynucleotide kinase (Boehringer) and was puri-
fied in Tris-EDTA buffer that contained NaCl (100 mM) using G-50 resin
columns (Whatman). Typically, 5  l (5–10  g) of hepatic nuclear extract
were incubated with 100,000 counts/min of 32P-labeled oligonucleotides
(0.5 ng) for 1–2 h at room temperature in a buffer that contained 10 mM
Tris, pH 7.6, 10% glycerol, 1 mM EDTA, 1 mg/ml BSA, and 0.2% Noni-
det P-40. Additionally, 2–4  g of poly(dI-dC) (Boehringer) were added to
the mixture as nonspecific competitor DNA. Protein-DNA complexes
were resolved on 4% nondenaturing polyacrylamide gels in 0.4  running
buffer that contained 450 mM Tris borate and 1  M EDTA, pH 8.0. Gels
were dried after electrophoresis and subjected to autoradiography.
Statistical analysis. Results are expressed as the mean   SEM. Group
comparisons were performed using Student’s t test or analysis of variance.
Differences were considered significant at P   0.05.
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